AtriCure price target raised to $58 from $57 at UBS

UBS raised the firm’s price target on AtriCure to $58 from $57 and keeps a Buy rating on the shares. AtriCure delivered a solid Q4, with sales up 21% and closing out a year in which the company grew 21%, the analyst tells investors in a research note. The firm believes sales upside is sustainable on what is already mid-teens growth estimates and has conviction in the company’s ability to drive improving leverage from here.